ライフサイエンスコーパス: ischemic cardiomyopathy

1 iovascular disease outcomes in patients with ischemic cardiomyopathy.

2 d cardiac function in a preclinical model of ischemic cardiomyopathy.

3 l range, could provide protective effects in ischemic cardiomyopathy.

4 D34(+) cell transplantation in patients with ischemic cardiomyopathy.

5 ts with nonischemic and 15% of patients with ischemic cardiomyopathy.

6 patients with nonischemic cardiomyopathy and ischemic cardiomyopathy.

7 nces left ventricular function in a model of ischemic cardiomyopathy.

8 with poor prognosis on the effect of CABG in ischemic cardiomyopathy.

9 elated with VA inducibility in patients with ischemic cardiomyopathy.

10 nd better exercise capacity in patients with ischemic cardiomyopathy.

11 ciated with VA inducibility in patients with ischemic cardiomyopathy.

12 eventually become irreversible and result in ischemic cardiomyopathy.

13 ltered in failing human hearts and mice with ischemic cardiomyopathy.

14 are beneficial in a porcine model of chronic ischemic cardiomyopathy.

15 ving heart failure symptoms in patients with ischemic cardiomyopathy.

16 nfirms the benefit of CABG for patients with ischemic cardiomyopathy.

17 ) patients affected by non-end stage dilated ischemic cardiomyopathy.

18 moderate long-term efficacy in patients with ischemic cardiomyopathy.

19 in the hearts of controls and patients with ischemic cardiomyopathy.

20 tal prognostic value in patients with severe ischemic cardiomyopathy.

21 o long-term outcome in patients with chronic ischemic cardiomyopathy.

22 e to CRT both for dilated cardiomyopathy and ischemic cardiomyopathy.

23 n preserving ventricular function in porcine ischemic cardiomyopathy.

24 sults to a broad population of patients with ischemic cardiomyopathy.

25 rysm formation (e.g., sarcoidosis) may mimic ischemic cardiomyopathy.

26 nance images to predict VAs in patients with ischemic cardiomyopathy.

27 um enhancement cardiac magnetic resonance in ischemic cardiomyopathy.

28 nefit of bone marrow-derived hMSC in chronic ischemic cardiomyopathy.

29 ous CPCs in patients with old MI and chronic ischemic cardiomyopathy.

30 he role of cardiac surgery for patients with ischemic cardiomyopathy.

31 tely reduces mitral regurgitation in porcine ischemic cardiomyopathy.

32 ary vessels and improve CBF in patients with ischemic cardiomyopathy.

33 ated cardiomyopathy, and 51 genes/5 ncRNA in ischemic cardiomyopathy.

34 ablished in a variety of aortic diseases and ischemic cardiomyopathy.

35 s after myocardial infarction and in chronic ischemic cardiomyopathy.

36 ue to reduce mitral regurgitation in porcine ischemic cardiomyopathy.

37 model of ischemic heart disease and in human ischemic cardiomyopathy.

38 ntable cardioverter-defibrillator therapy in ischemic cardiomyopathy.

39 entricular tachycardia (VT) in patients with ischemic cardiomyopathy.

40 progression of LV dysfunction in swine with ischemic cardiomyopathy.

41 dent predictor of mortality in patients with ischemic cardiomyopathy.

42 a higher proportion of diabetes mellitus and ischemic cardiomyopathy.

43 se and arrhythmic mortality in patients with ischemic cardiomyopathy.

44 ) were 56 +/- 13 years and 71% male; 49% had ischemic cardiomyopathy.

45 dium and ameliorate heart failure in chronic ischemic cardiomyopathy.

46 is a treatment option for moderate-to-severe ischemic cardiomyopathy.

47 tribute to arrhythmic death in patients with ischemic cardiomyopathy.

48 failure (HF) and is a known risk factor for ischemic cardiomyopathy.

49 giogenesis offers the potential for treating ischemic cardiomyopathy.

50 an increase cardiac performance in rats with ischemic cardiomyopathy.

51 chemic myocardium in patients with end-stage ischemic cardiomyopathy.

52 by gene transfer of TIMP-1 in a rat model of ischemic cardiomyopathy.

53 d preserves cardiac function and geometry in ischemic cardiomyopathy.

54 ransfected with AdVEGF-165 in a rat model of ischemic cardiomyopathy.

55 ening appears to be limited to patients with ischemic cardiomyopathy.

56 ole for reactive O(2) in the pathogenesis of ischemic cardiomyopathy.

57 ognostically powerful clinical definition of ischemic cardiomyopathy.

58 rapy for left ventricular dysfunction due to ischemic cardiomyopathy.

59 however, there is no uniform definition for ischemic cardiomyopathy.

60 hy, but remains impaired in those with prior ischemic cardiomyopathy.

61 a long-term benefit of CABG in patients with ischemic cardiomyopathy.

62 hy, 151 in dilated cardiomyopathy, and 55 in ischemic cardiomyopathy.

63 T ablation procedure data from patients with ischemic cardiomyopathy.

64 peri-infarct size with clinical outcomes in ischemic cardiomyopathy.

65 s scar size and improves cardiac function in ischemic cardiomyopathy.

66 cells identically delivered in patients with ischemic cardiomyopathy.

67 d novel phenotypes for long-term outcomes in ischemic cardiomyopathy.

68 e therapeutic solutions to treat CVD such as ischemic cardiomyopathy.

69 tegorized as Chagasic, other nonischemic, or ischemic cardiomyopathy.

70 ion in animal models of both AMI and chronic ischemic cardiomyopathy.

71 plantable cardioverter defibrillator AND non-ischemic cardiomyopathy.

72 tality in primary-prevention candidates with ischemic cardiomyopathy.

73 er nonischemic cardiomyopathy, and 1057 with ischemic cardiomyopathy.

74 gnificantly increased in human patients with ischemic cardiomyopathy.

75 nic disease states such as stable angina and ischemic cardiomyopathy.

76 assisted strategy in patients with suspected ischemic cardiomyopathy.

77 arrow cells into the hearts of patients with ischemic cardiomyopathy.

78 m 15 subjects with hypertrophic, dilated, or ischemic cardiomyopathies.

79 year HR, 1.44; 3-year HR, 1.37; P<0.001) and ischemic cardiomyopathy (1-year HR, 1.39; 3-year HR, 1.4

80 nic right ventricular cardiomyopathy than in ischemic cardiomyopathy (100% versus 86% versus 53%; P <

81 LAVAs were observed in 44 of 49 patients (15 ischemic cardiomyopathy, 15 nonischemic cardiomyopathy,

82 Among all patients (164 ischemic cardiomyopathy, 150 nonischemic dilated cardiom

83 Scarring was found in 100% of patients with ischemic cardiomyopathy (28 of 28) but in only 12% with

84 Of the 30 VTs, 24 (6 with ischemic cardiomyopathy, 3 with idiopathic cardiomyopath

85 impaired in transplant recipients with prior ischemic cardiomyopathy (5.5 +/- 1.5%, p = 0.001 compare

86 ion fraction (30% versus 38%), more frequent ischemic cardiomyopathy (58% versus 45%), more history o

87 n average age of 51 years, had predominately ischemic cardiomyopathy (63%), and a mean left ventricul

88 2 yr old) were included, most of them having ischemic cardiomyopathy (65.4%).

89 mostly of white men (72%) and patients with ischemic cardiomyopathy (72%).

90 diabetes mellitus (36% versus 18%; P=0.045), ischemic cardiomyopathy (86% versus 52%; P=0.002), chron

91 +/-11.4 years, 82.1% were male, 42.5% had an ischemic cardiomyopathy, 87.7% were bridge to transplant

92 higher in nonischemic cardiomyopathy than in ischemic cardiomyopathy (93% versus 27%; P < 0.001).

93 Patients with stable ischemic cardiomyopathy, a left ventricular ejection fra

94 ed with increased mortality in patients with ischemic cardiomyopathy (adjusted hazard ratio 1.33, 95%

95 case of a 71-year-old male with a history of ischemic cardiomyopathy after left ventricular assist de

96 ll-cause mortality in patients with advanced ischemic cardiomyopathy, after adjusting for clinical ri

97 ention plays a pivotal role in patients with ischemic cardiomyopathy, although these interventions ar

98 Precordial ECGs were recorded from 15 ischemic cardiomyopathy and 15 Brugada syndrome (type 1

99 was 60 +/- 12 years, 83% were males, 52% had ischemic cardiomyopathy and 54% were destination therapy

100 nths, 70% freedom from VT recurrence (80% in ischemic cardiomyopathy and 63% in nonischemic cardiomyo

101 fty-nine percent of these patients had acute ischemic cardiomyopathy and 66% underwent cardiopulmonar

102 ed, controlled trial involving patients with ischemic cardiomyopathy and an ICD who had ventricular t

103 In patients with ischemic cardiomyopathy and an ICD who had ventricular t

104 hmias by 3 months was 3% among patients with ischemic cardiomyopathy and congenital/inherited heart d

105 bypass grafting (CABG) for the patient with ischemic cardiomyopathy and congestive heart failure.

106 mic cardiomyopathy was limited to those with ischemic cardiomyopathy and diabetes mellitus (RR 1.37,

107 When patients with ischemic cardiomyopathy and diabetes mellitus were exclu

108 n identified patients within the cohort with ischemic cardiomyopathy and diabetes mellitus, with impr

109 y be particularly important in patients with ischemic cardiomyopathy and diabetes mellitus.

110 Methods: Fifteen patients with ischemic cardiomyopathy and drug-refractory VT underwent

111 atients (81% male, age 62 +/- 13 years) with ischemic cardiomyopathy and ES underwent catheter ablati

112 ese remodeling processes ultimately leads to ischemic cardiomyopathy and heart failure (HF).

113 In pathological conditions such as ischemic cardiomyopathy and heart failure, differentiati

114 therapies for prevalent conditions, such as ischemic cardiomyopathy and heart failure.

115 eutic approach to prevent the progression of ischemic cardiomyopathy and heart failure.

116 hypothesized that Tregs are dysfunctional in ischemic cardiomyopathy and HF, and they promote immune

117 -controlled study involving 65 patients with ischemic cardiomyopathy and left ventricular (LV) ejecti

118 ine, male patients had a higher incidence of ischemic cardiomyopathy and longer QRS duration.

119 ppeared to be safe for patients with chronic ischemic cardiomyopathy and LV dysfunction.

120 Patients with ischemic cardiomyopathy and multiple VT were studied.

121 ous cardiovascular disease states, including ischemic cardiomyopathy and myocardial hibernation (5, 6

122 In patients with ischemic cardiomyopathy and no prior history of ventricu

123 over transthoracic echocardiography (TTE) in ischemic cardiomyopathy and nonischemic dilated cardiomy

124 on of cardiac AC(VI) expression in mice with ischemic cardiomyopathy and severe CHF improves function

125 ith reduced ejection fraction are those with ischemic cardiomyopathy and severe left ventricular syst

126 both post-acute myocardial infarction and in ischemic cardiomyopathy and that these effects are cause

127 Patients with ischemic cardiomyopathy and those with narrower QRS, in

128 t differ significantly between patients with ischemic cardiomyopathy and those with nonischemic cardi

129 n in a large cohort of patients with chronic ischemic cardiomyopathy and to determine the incremental

130 In 22 patients with ischemic cardiomyopathy and VT, high-density mapping was

131 onischemic cardiomyopathy, 6 (4414 patients) ischemic cardiomyopathy, and 1 (2521 patients) both type

132 female, 10% LV ejection fraction </=25%, 55% ischemic cardiomyopathy, and 71% left bundle-branch bloc

133 nterquartile range, 58-75) years, 40% had an ischemic cardiomyopathy, and median HF duration was 2.8

134 ntricular ejection fraction was 20%, 81% had ischemic cardiomyopathy, and PAINESD score was 18+/-5.

135 ecial focus on cardiac magnetic resonance in ischemic cardiomyopathy, and provides an outlook on how

136 HIV infection, diabetes mellitus, history of ischemic cardiomyopathy, and undergoing percutaneous cor

137 he setting of severe heart failure caused by ischemic cardiomyopathy are unknown.

138 ] trial) and establish this porcine model of ischemic cardiomyopathy as a useful and clinically relev

139 d with patients aged less than 70 years with ischemic cardiomyopathy as indicated using logistic regr

140 on fraction and end-diastolic diameter, sex, ischemic cardiomyopathy, atrial fibrillation, and epicar

141 LGE-CMR was performed in 23 patients with ischemic cardiomyopathy before VT ablation.

142 In ischemic cardiomyopathy, cardiac magnetic resonance asse

143 travenous administration of TRH to rats with ischemic cardiomyopathy caused a significant increase in

144 ricular tissue from patients with dilated or ischemic cardiomyopathy compared to nonfailing donors.

145 The increased mortality in patients with ischemic cardiomyopathy compared with nonischemic cardio

146 increased more than 4-fold in the RVs of the ischemic cardiomyopathy compared with the nonfailing gro

147 n at subendocardium was lower in hearts with ischemic cardiomyopathy compared with those with nonisch

148 ays an important role in the pathogenesis of ischemic cardiomyopathy, contributing to systolic and di

149 MI) presentation, stress cardiomyopathy, non-ischemic cardiomyopathy, coronary spasm, or nonspecific

150 ing hypertrophic obstructive cardiomyopathy, ischemic cardiomyopathy, dilated cardiomyopathy, and 9 c

151 Patients with established ischemic cardiomyopathy do not require electrophysiologi

152 on) is difficult to predict in patients with ischemic cardiomyopathy either by clinical tools or by a

153 hymal stem cells (hMSCs) have been tested in ischemic cardiomyopathy, few studies exist in chronic no

154 l biomarker able to predict the evolution of ischemic cardiomyopathy following revascularization.

155 of CAD and to develop the best definition of ischemic cardiomyopathy for prognostic purposes.

156 tor of surgical revascularization benefit in ischemic cardiomyopathy has recently been questioned in

157 ow mononuclear cells (BMCs) in patients with ischemic cardiomyopathy have demonstrated safety and sug

158 Patients with ischemic cardiomyopathy have larger areas of abnormal in

159 Among patients with ischemic cardiomyopathy, hibernating, but not ischemic,

160 ovasculogenic myocardial repair in models of ischemic cardiomyopathy; however, these molecules have s

161 VT circuits in patients with ischemic cardiomyopathies (ICM) and non-ICM (NICM) may d

162 agnosed nonischemic cardiomyopathy (NICM) or ischemic cardiomyopathy (ICM) against sudden cardiac dea

163 cardioverter defibrillator (ICD) therapy in ischemic cardiomyopathy (ICM) and nonischemic cardiomyop

164 nts at higher risk of future events, both in ischemic cardiomyopathy (ICM) and nonischemic dilated ca

165 lar fibrillation (VF) storm in patients with ischemic cardiomyopathy (ICM) and the results of targete

166 butamine on left ventricular (LV) filling in ischemic cardiomyopathy (ICM) and to determine whether r

167 al conduction velocity (CV) in patients with ischemic cardiomyopathy (ICM) and ventricular tachycardi

168 s with nonischemic cardiomyopathy (NICM) and ischemic cardiomyopathy (ICM) etiologies and evaluate th

169 erimental models; however, its role in human ischemic cardiomyopathy (ICM) has never been analysed.

170 eir native heart function, but the impact of ischemic cardiomyopathy (ICM) has not been specifically

171 ls examining the management of patients with ischemic cardiomyopathy (ICM) have questioned both the a

172 ion-related signaling in the pathogenesis of ischemic cardiomyopathy (ICM) in animal models, substant

173 cy of mesenchymal stem cell (MSC) therapy in ischemic cardiomyopathy (ICM) is controversial.

174 leads to early improvement in LV function in ischemic cardiomyopathy (ICM) patients.

175 , respectively) as well as 161 patients with ischemic cardiomyopathy (ICM) undergoing CRT (n = 258) w

176 s with nonischemic cardiomyopathy (NICM) and ischemic cardiomyopathy (ICM), myocarditis patients were

177 In patients with an ischemic cardiomyopathy (ICM), the combination of late p

178 In contrast, among 50 patients with ischemic cardiomyopathy (ICM), the heart weight index wa

179 n of VT in patients with NIDCM compared with ischemic cardiomyopathy (ICM).

180 (MSCs) are under evaluation as a therapy for ischemic cardiomyopathy (ICM).

181 nchronization therapy (CRT) in patients with ischemic cardiomyopathy (ICM).

182 cardiovascular events (CVE) in patients with ischemic cardiomyopathy (ICM).

183 le and nonviable myocardium in patients with ischemic cardiomyopathy (ICM).

184 ricular arrhythmias compared with those with ischemic cardiomyopathy (ICM).

185 (non-betaB-CHF) patients and in 4 subgroups: ischemic cardiomyopathy (ICM, n=10), nonischemic dilated

186 s with dilated cardiomyopathy (DCM, n=14) or ischemic cardiomyopathy (ICM, n=16) at the time of impla

187 h significant mitral regurgitation caused by ischemic cardiomyopathy (ICM-MR) and by idiopathic dilat

188 ients with end-stage heart failure caused by ischemic cardiomyopathy (ICM; n=16) or non-ICM (n=22) ca

189 s with chronic postinfarction heart failure (ischemic cardiomyopathy [ICM]).

190 Forty-six patients (18 ischemic cardiomyopathy [ICM], 13 nonischemic dilated ca

191 patients with end-stage heart failure due to ischemic cardiomyopathy (IHD) or dilated cardiomyopathy

192 was significantly reduced in human end-stage ischemic cardiomyopathy in comparison to nonfailing myoc

193 In a mouse model of ischemic cardiomyopathy induced by repetitive ischemia/r

194 ngest associations observed in patients with ischemic cardiomyopathy (interaction P=0.008) and New Yo

195 lear cells are safe and effective in chronic ischemic cardiomyopathy is controversial.

196 The pathophysiological substrate of ischemic cardiomyopathy is heterogeneous, varying from p

197 The long-term prognosis of patients with ischemic cardiomyopathy is highly variable, depending on

198 efficacy of bypass surgery in patients with ischemic cardiomyopathy is not easily predictable; preop

199 Ischemic cardiomyopathy is the major cause of heart fail

200 Chronic left ventricular dysfunction in ischemic cardiomyopathy is the result of a mixture of sc

201 ED) in patients with heart failure caused by ischemic cardiomyopathy is the same in patients of diffe

202 (control group), as well as 36 patients with ischemic cardiomyopathy (ischemic group).

203 A total of 362 patients with ischemic cardiomyopathy (left ventricular dysfunction wi

204 ed a prospective cohort of 768 patients with ischemic cardiomyopathy (left ventricular ejection fract

205 We enrolled 768 consecutive patients with ischemic cardiomyopathy (left ventricular ejection fract

206 York Heart Association functional class III ischemic cardiomyopathy (left ventricular ejection fract

207 ithout DM, those with DM had higher rates of ischemic cardiomyopathy, LVAD implantation as destinatio

208 rospective study that enrolled patients with ischemic cardiomyopathy (LVEF < or =0.40) and nonsustain

209 We prospectively enrolled 204 subjects with ischemic cardiomyopathy (LVEF </=35%) eligible for prima

210 ss of functionally competent CSCs in chronic ischemic cardiomyopathy may underlie the progressive fun

211 s were included (mean age, 63; 95% male; 73% ischemic cardiomyopathy; mean left ventricular ejection

212 proved clinical status in some patients with ischemic cardiomyopathy, mild-to-moderate symptoms, narr

213 In an ischemic cardiomyopathy model, mice 4 weeks post-myocard

214 In the postinfarct ischemic cardiomyopathy model, VEGFR-1 deficiency suppor

215 by clinical factors, including advanced age, ischemic cardiomyopathy, more severe heart failure statu

216 to traditional indices such as low LVEF and ischemic cardiomyopathy, multivariable analysis showed t

217 nonischemic cardiomyopathy (n = 10) or prior ischemic cardiomyopathy (n = 10) and normal controls (n

218 ither nonischemic cardiomyopathy (n = 10) or ischemic cardiomyopathy (n = 7), cardiac transplant reci

219 on (n=2), hypertrophic cardiomyopathy (n=1), ischemic cardiomyopathy (n=1), and arrhythmogenic right

220 diac causes was ascertained in subjects with ischemic cardiomyopathy (n=204) eligible for an implanta

221 re isolated from patients with CHF caused by ischemic cardiomyopathy (n=45) and healthy subjects (n=3

222 pathies associated with inflammation (n=27), ischemic cardiomyopathy (n=8), and the normal heart (n=1

223 Patients had ischemic cardiomyopathy (New York Heart Association [NYH

224 Seventeen subjects with ischemic cardiomyopathy, New York Heart Association clas

225 In Medicare patients, RBBB, ischemic cardiomyopathy, New York Heart Association clas

226 (statin) therapy on surrogate markers in non-ischemic cardiomyopathy (NICM) patients and average low-

227 ponse was 20.0% (greater age, comorbidities, ischemic cardiomyopathy, non-left bundle branch block, a

228 In an animal model of ischemic cardiomyopathy, obliteration of a conductive is

229 nors and transplant recipients with endstage ischemic cardiomyopathy or idiopathic dilated cardiomyop

230 Patients with heart failure with either ischemic cardiomyopathy or nonischemic cardiomyopathy ha

231 e hundred fourteen consecutive patients with ischemic cardiomyopathy or nonischemic dilated cardiomyo

232 gical, and functional changes reminiscent of ischemic cardiomyopathy over time.

233 for AHR and RR in dilated cardiomyopathy and ischemic cardiomyopathy (p = 0.01 and p = 0.006) was see

234 rm survival was a pretransplant diagnosis of ischemic cardiomyopathy (p = 0.04).

235 Thirty patients with a history of ischemic cardiomyopathy participated in a phase I, nonra

236 helpful in refining VA risk in patients with ischemic cardiomyopathy, particularly to identify low-ri

237 human left ventricular tissue acquired from ischemic cardiomyopathy patients at cardiac transplantat

238 Analysis of shared frequency in ischemic cardiomyopathy patients with anteroseptal (n=4)

239 developed and applied retrospectively to 29 ischemic cardiomyopathy patients with contrast-enhanced

240 One hundred twenty-two consecutive ischemic cardiomyopathy patients with left ventricular e

241 rty-four dilated cardiomyopathy patients, 30 ischemic cardiomyopathy patients, and 36 controls underw

242 affected 40% of the inferior segments in all ischemic cardiomyopathy patients, whereas they affected

243 significantly increases freedom from VAs in ischemic cardiomyopathy patients.

244 icantly down-regulated in cardiac tissues of ischemic cardiomyopathy patients.

245 patients with nonischemic cardiomyopathy and ischemic cardiomyopathy, patients with CCMP were overwhe

246 In ischemic cardiomyopathy, persistence of restrictive fill

247 In advanced ischemic cardiomyopathy, PI% is a powerful independent a

248 cute myocardial infarction (AMI) and chronic ischemic cardiomyopathy preclinical studies (58 studies;

249 cute myocardial infarction (AMI) and chronic ischemic cardiomyopathy preclinical studies (58 studies;

250 Ischemic cardiomyopathy predominated (65%), and 29% had

251 ional mitral regurgitation (MR) secondary to ischemic cardiomyopathy (prior bypass surgery in all cas

252 ears; LV ejection fraction, 30+/-6%; 18 with ischemic cardiomyopathy; QRS, 181+/-25 ms; all mean+/-SD

253 t component that correlated with TCL in both ischemic cardiomyopathy (r=-0.5, P=0.006) and nonischemi

254 Patients with more advanced ischemic cardiomyopathy receive greater benefit from CAB

255 METHODS AND Thirty patients with ischemic cardiomyopathy received in a blinded manner eit

256 Thirty patients with ischemic cardiomyopathy referred for primary prevention

257 atients (all male; median age 60 years) with ischemic cardiomyopathy, refractory heart failure, and l

258 isk for all-cause mortality in patients with ischemic cardiomyopathy, (relative risk [RR] 1.37, 95% c

259 Interactions of age, sex, ischemic cardiomyopathy, renal failure, or QRS duration

260 in Foxp3-diphtheria toxin receptor mice with ischemic cardiomyopathy reversed LV remodeling and dysfu

261 humans (Stem Cell Infusion in Patients with Ischemic CardiOmyopathy [SCIPIO] trial) and establish th

262 1 trial (Stem Cell Infusion in Patients with Ischemic cardiOmyopathy [SCIPIO]) of autologous CSCs for

263 rly VF in patients with Brugada syndrome and ischemic cardiomyopathy shows a predictable sequence in

264 In ischemic cardiomyopathy, sympathetic denervation assesse

265 A definition of ischemic cardiomyopathy that incorporated this definitio

266 In a cohort of patients with ischemic cardiomyopathy, the rates of death from any cau

267 In patients with ischemic cardiomyopathy, the reduced amount of viable my

268 modeling in mice with large infarcts, and in ischemic cardiomyopathy, they improve LV function, effec

269 ors of recovery included: age <50 years, non-ischemic cardiomyopathy, time from cardiac diagnosis <2

270 with 12 months of follow-up in subjects with ischemic cardiomyopathy to see if JVS-100 improves clini

271 RBBB and ischemic cardiomyopathy together had twice the adjusted

272 e left ventricular maps from 6 patients with ischemic cardiomyopathy (total 9 VTs) and were compared

273 In patients with severe ischemic cardiomyopathy treated with PCI, all-cause mort

274 The Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE)

275 dia Trial (MUSTT), the Defibrillators in Non-Ischemic Cardiomyopathy Treatment Evaluation (DEFINITE)

276 olled in the DEFINITE (DEFIbrillators in Non-Ischemic cardiomyopathy Treatment Evaluation) study.

277 Forty patients with ischemic cardiomyopathy underwent (201)Tl scintigraphy (

278 Seventeen patients with known ischemic cardiomyopathy underwent dynamic (15)O-water an

279 Methods Patients with ischemic cardiomyopathy underwent mapping using the ultr

280 ote increased vascular tissue in humans with ischemic cardiomyopathy via direct injection.

281 Ischemic cardiomyopathy was created in 10 additional swi

282 Ischemic cardiomyopathy was more frequent in the HIV gro

283 In human hearts with end-stage ischemic cardiomyopathy, we find that BIN1 is also 50% r

284 ces of explanted hearts from 3 patients with ischemic cardiomyopathy were incubated in vitro with FBL

285 Lower rates of ischemic cardiomyopathy were observed (13% versus 41%; P

286 Gottingen swine with experimental ischemic cardiomyopathy were randomized to receive trans

287 e patients undergoing CRT (21 dilated and 12 ischemic cardiomyopathy) were studied.

288 predictor of poor outcomes in patients with ischemic cardiomyopathy; whether correcting it at the ti

289 tool for identifying high-risk patients with ischemic cardiomyopathy who are likely to benefit from i

290 rdial viability in identifying patients with ischemic cardiomyopathy who might benefit from surgical

291 erent mortality benefits among patients with ischemic cardiomyopathy who screen negative and non-nega

292 Subjects with ischemic cardiomyopathy who were scheduled for placement

293 Standardization of the definition of ischemic cardiomyopathy will be useful in the conduct an

294 highly effective therapy in the treatment of ischemic cardiomyopathy with excellent five-year outcome

295 rossover study, we enrolled 33 patients with ischemic cardiomyopathy with New York Heart Association

296 ctional recovery in a swine model of chronic ischemic cardiomyopathy without adverse immunologic reac

297 ents with CS (n=450), 30% had AMICS, 18% had ischemic cardiomyopathy without AMI, 28% had nonischemic

298 iary referral centers, 228 patients with non-ischemic cardiomyopathy without history of CHF were stud

299 In patients with non-ischemic cardiomyopathy without history of CHF, myocardi

300 of myocardial fibrosis in patients with non-ischemic cardiomyopathy without history of congestive he